The microbiome in prostate inflammation and prostate cancer

The microbiome in prostate inflammation and prostate cancerThe microbiome in prostate inflammation and prostate cancer, Published online: 23 May 2018; doi:10.1038/s41391-018-0041-1The microbiome in prostate inflammation and prostate cancer
Source: Prostate Cancer and Prostatic Diseases - Category: Urology & Nephrology Authors: Source Type: research

Related Links:

Conclusions: BT combined with HT can increase the bPFS rates of patients with localized prostate cancer, but it does not improve patients' OS rates.
Source: Frontiers in Oncology - Category: Cancer & Oncology Source Type: research
PROSTATE cancer is the most common type of cancer in men in Britain, with more than 40,000 new cases diagnosed each year. For a man who experiences an unusual habit at night, it could mean they're at risk. What is it?
Source: Daily Express - Health - Category: Consumer Health News Source Type: news
Publication date: Available online 17 February 2020Source: Journal of the Formosan Medical AssociationAuthor(s): Yu-Chuan Lu, Ming-Chieh Kuo, Jian-Hua Hong, Fu-Shan Jaw, Chao-Yuan Huang, Jason Chia-Hsien Cheng, Hsiu-Ni KungBackground/PurposeThe inflammatory milieu has been firmly established to affect cancer progression. However, the connection between natural killer (NK) cells and prostate cancer (PCa) has not been elucidated.MethodsProspective data on NK cell activity (NKA) and NK cell subset distribution patterns were evaluated from 51 patients treated with robot-assisted laparoscopic radical prostatectomy. Whole-blood ...
Source: Journal of the Formosan Medical Association - Category: General Medicine Source Type: research
AbstractPurposeTo analyze the differences in toxicity and biochemical relapse-free survival with hypofractionated radiotherapy with three-dimensional radiotherapy (3D-CRT) or volumetric arc therapy (VMAT) for prostate cancer taking into account comorbidity measured using the Charlson Comorbidity Index (CCI).MethodsFrom January 2011 to June 2016, 451 patients with prostate cancer were treated with 60  Gy (20 daily fractions). VMAT or 3D-CRT was used. Distribution by stage: 17% low-risk, 27.2% intermediate-risk; 39.2% high-risk, 16.6% very high-risk. Mean CCI was 3.4.ResultsWith a median follow up of 51  months, mo...
Source: Clinical and Translational Oncology - Category: Cancer & Oncology Source Type: research
Cellular Analytics, a biotechnology company in Ontario, Canada, has unveiled a novel liquid biopsy test for mesothelioma that could lead to more effective management of this rare cancer. The test has the potential to produce a much-earlier diagnosis of disease and the ability to personalize treatment and better predict a patient’s response to specific therapies. “We could change completely how this disease is viewed,” Dr. Brent Zanke, a specialist in diagnostic oncology and chief executive officer of Cellular Analytics, told The Mesothelioma Center at Asbestos.com. “It’s a proactive way to get...
Source: Asbestos and Mesothelioma News - Category: Environmental Health Authors: Source Type: news
(Oxford University Press USA) A new study in JNCI: Journal of the National Cancer Institute, published by Oxford University Press, finds significant benefits to lengthening the amount of time between prostate cancer screenings for men.
Source: EurekAlert! - Cancer - Category: Cancer & Oncology Source Type: news
Patches made from human placenta could prevent men becoming impotent following prostate cancer surgery. Incontinence and erectile dysfunction can occur in up to seven in ten men.
Source: the Mail online | Health - Category: Consumer Health News Source Type: news
ConclusionThe success rate and functional outcome after BMGU for radiation-induced strictures were reasonable. However, compared to existing long-term data on non-irradiated patients, the outcome is impaired and patients should be counseled accordingly.
Source: World Journal of Urology - Category: Urology & Nephrology Source Type: research
er Qing Kay Li Hui Zhang The emergence of castration-resistance is one of the major challenges in the management of patients with advanced prostate cancer. Although the spectrum of systemic therapies that are available for use alongside androgen deprivation for treatment of castration-resistant prostate cancer (CRPC) is expanding, none of these regimens are curative. Therefore, it is imperative to apply systems approaches to identify and understand the mechanisms that contribute to the development of CRPC. Using comprehensive proteomic approaches, we show that a glycosylation-related enzyme, alpha (1,6) fucosyltran...
Source: Cancers - Category: Cancer & Oncology Authors: Tags: Article Source Type: research
Conclusions: Diabetes increased the risk of all-cause mortality among breast, prostate, and colorectal cancer survivors, not for pre- or post-diagnosis diabetes. Greater attention on diabetes management is warranted in cancer survivors with diabetes.
Source: Frontiers in Endocrinology - Category: Endocrinology Source Type: research
More News: Cancer | Cancer & Oncology | Prostate Cancer | Urology & Nephrology